Surgery is most often the first part of the treatment plan. Aneurosurgeon, a surgeon who specializes in operating on the brain, tries to remove as much of the tumor as possible. Because glioblastomas often develop in healthy brain tissue, the neurosurgeon may not be able to remove all of t...
Glioblastoma (GBM) is a fast-growing, highly infiltrative, and hypoxic tumor that is resistant to conventional treatment owing to these biological characteristics. A key problem in the treatment of GBM is the radiation tolerance of the normal brain tissue surrounding the tumor. However, recent ...
Mirimanoff, M.D., for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group* From the Centre Hospitalier UniversitaireVaudois, Lausanne, Switzerland (R.S.,R-C.J., R.O.M.); Princess...
The summarized reasons for the lack of effective regimens in recurrent GBM were listed in Introduction. The intrinsic resistance of tumor cells; The molecular heterogeneity; The reduced concentration of effective treatment due to the blood-brain-tumor barrier; The difficult prediction of clinical efficac...
tumor cells from each patient can be expandedin vitroand used to screen or test the existing drugs or their combination to find the best treatment for each patient. However, the widespread use of this approach highly relies on technologies that can efficiently and cost-effectively culture TICs fo...
brain TILs. (Figure3c). This result suggests thatin situoHSV treatment promotes tumor-infiltration or proliferation of tumor specific CD8+ T cells. As expected, there was also an increase in CD8+ T cells specific for the oHSV antigen, gB49823(Fig.3b,d). Specifically, at 7 days this ...
model in which neurons prompt the expression of genes from glioma tumors that subsequently drive infiltration and their own synaptic activity,” Huang-Hobbs concluded. “A better understanding of the two-way conversation between GBM and CPNs is an importan...
G. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 36, 1046–1069 (2004). CAS Google Scholar van Tellingen, O. et al. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 19,...
Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed Syne...
changes outweighing the benefits of total resection [11,12]. The use of chemotherapeutic agents is also limited due to limited infiltration of drugs through the highly selective blood brain barrier (BBB) [13]. Currently, the only therapeutic agents approved for GBM treatment are TMZ, carmustine ...